Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

NCT04659603 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04659603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04659603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
March 29, 2021
Completion date
January 19, 2025
Enrollment
50 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic, pancreatic carcinoma metastatic